Publication Month: Mar 2020 | Report Code: TIPRE00008485 | No. of Pages: 183 | Category: Pharmaceuticals | Status: Published
Neurological diseases having less diagnostics and treatment options affecting small number of population is termed as rare neurological diseases. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. Amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, Huntington's disease are few examples of rare neurological conditions. The global rare neurological disease treatment market is driven by factors such as rising prevalence of rare neurological diseases and favorable pipeline drugs and robust research activities for the treatment of rare neurological diseases. However, high treatment cost for rare neurological diseases are likely to show negative impact on market growth during the forecast period.
Get more information on this report :
In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. According to a data published by National Institutes of Neurological Disorders and Stroke in 2019, 7,000 rare neurological diseases have been registered in the US. Additionally, according to the same study, these conditions are responsible for significant number of morbidity and mortality.
Deprivation of sleep, psychological stress, an inherited genetic fault, sudden change in sleep patterns, and aging are the main factors that accelerate the prevalence of rare neurological diseases. Considering these factors, the elderly population is highly vulnerable for neurological conditions. For instance, as per the study published in Annals of Neurology in 2017, around 100 million US populations was affected by the rare neurological disease in 2011. Moreover, these diseases are responsible to increase the morbidity and disability, which affects the economic condition of the country. Neurological sleep related disorders are expected to increase in coming years owing to the increasing ageing population across the world. According to the data published by National Institute of Health (NIH) in 2019, approximately 40 million Americans suffer from neurological diseases in the US, whereas additional 20 million people experience occasional sleeping problems.
Based on indication, the rare neurological disease treatment market is segmented into narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchene muscular dystrophy, and other indications. The Alzheimer’s disease segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period. The disease accounts for nearly 60% to 80% of all dementia cases and is widely seen among the aging population.
Get more information on this report :
Based on drug type, the rare neurological disease treatment market is segmented into organic compounds, and biologics. The biologics segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period.
Based on distribution channel, the rare neurological disease treatment market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019 however, retail pharmacies is estimated to register the highest CAGR in the market during the forecast period.
Based on mode of administration, the rare neurological disease treatment market is segmented into oral and injectable. The oral segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period
|Market Size Value in||US$ 7,300.12 Million in 2019|
|Market Size Value by||US$ 13,830.96 Million by 2027|
|Growth rate||CAGR of 8.5% from 2020-2027|
|No. of Pages||183|
|No. of Tables||95|
|No. of Charts & Figures||72|
|Historical data available||Yes|
|Segments covered||Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the rare neurological disease treatment market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name globally.
The List of Companies - Rare Neurological Disease Treatment Market